Table 5.
Echocardiographic analysis 22 weeks after the induction of aorto-caval fistula (ACF) or sham-operation and after 20 weeks´ treatment with 14,15-epoxyeicosatrienoic acids analog (EET-A) and angiotensin-converting enzyme inhibitor (ACEi) alone or combined with EET-A.
| Group | |||||
|---|---|---|---|---|---|
| HanSD | TGR | ACF TGR | ACF TGR | ACF TGR | |
| +water | +water | +ACEi | +EET-A | +EET-A + ACEi | |
| Heart rate (min−1) | 372 ± 9 | 365 ± 18 | 363 ± 9 | 365 ± 11 | 368 ± 19 |
| LV diastolic diameter (mm) | 6.96 ± 0.22 | 7.09 ± 0.27 | 11.29 ± 0.31 # | 11.12 ± 0.51 # | 11.51 ± 0.29 # |
| LV systolic diameter (mm) | 3.78 ± 0.22 | 4.35 ± 0.39 | 7.55 ± 0.26 # | 7.63 ± 0.44 # | 7.69 ± 0.37 # |
| LV anterior wall thickness in diastole (mm) | 2.32 ± 0.06 | 3.05 ± 0.06 * | 2.06 ± 0.05 # | 2.25 ± 0.06 # | 1.87 ± 0.05 # |
| LV posterior wall thickness in diastole (mm) | 2.55 ± 0.06 | 3.07 ± 0.11 * | 2.08 ± 0.05 # | 2.12 ± 0.07 # | 2.02 ± 0.05 # |
| LV relative wall thickness | 0.738 ± 0.04 | 0.913 ± 0.04 * | 0.368 ± 0.02 # | 0.393 ± 0.02 # | 0.369 ± 0.03 # |
| LV ejection fraction (%) | 75.8 ± 1.9 | 71.6 ± 2.6 | 55.8 ± 1.6 # | 53.9 ± 1.4 # | 57.3 ± 1.5 # |
| LV fractional shortening (%) | 46.1 ± 1.7 | 44.6 ± 1.6 | 33.3 ± 0.7 # | 32.5 ± 1.1 # | 32.4 ± 0.8 # |
| LV stroke volume (µL) | 191 ± 11 | 174 ± 8 | 437 ± 22 # | 408 ± 29 # | 414 ± 31 # |
| Cardiac output (mL/min) | 69.9 ± 1.5 | 63.6 ± 4.2 | 158 ± 6.2 # | 152 ± 10.1 # | 155 ± 8.7 # |
| RV basal diameter in diastole (mm) | 3.06 ± 0.13 | 3.08 ± 0.11 | 6.65 ± 0.19 # | 5.81 ± 0.36 # | 5.41 ± 0.13 @ |
| RV midcavity diameter in diastole (mm) | 2.45 ± 0.11 | 2.49 ± 0.12 | 6.03 ± 0.16 # | 5.28 ± 0.21 # | 5.02 ± 0.12 @ |
| RV fractional area change (%) | 61.9 ± 5.8 | 65.1 ± 5.2 | 35.9 ± 1.1 # | 39.5 ± 1.6 # | 33.7 ± 1.4 # |
Values are means ± SEM. LV, left ventricle; RV, right ventricle; * p < 0.05 vs. sham-operated HanSD rats; # p < 0.05 vs. TGR + water; @ p < 0.05 vs. ACF TGR + ACEi.